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Abstract 
 
All the somatic cells composing a mammalian 
organism are genetically identical and contain the same 
DNA sequence. Nevertheless, they are able to adopt a 
distinct commitment, differentiate in a tissue specific 
way and respond to developmental cues, acquiring a 
terminal phenotype. At the end of the differentiation 
process, each cell is highly specialized and committed 
to a distinct determined fate. This is possible thanks to 
tissue-specific gene expression, timely regulated by 
epigenetic modifications, that gradually limit cell potency 
to a more restricted phenotype-related expression pattern. 
Complex chemical modifications of DNA, RNA and 
associated proteins, that determine activation or silencing 
of certain genes are responsible for the ‘epigenetic 
control’ that triggers the restriction of cell pluripotency, 
with the acquisition of the phenotypic definition and the 
preservation of its stability during subsequent cell 
divisions. The process is however reversible and may be 
modified by biochemical and biological manipulation, 
leading to the reactivation of hypermethylated 
pluripotency genes and inducing cells to transit from a 
terminally committed state to a higher plasticity one. 
These epigenetic regulatory mechanisms play a 
key role in embryonic development since they drive 
phenotype definition and tissue differentiation. At the 
same time, they are crucial for a better understanding of 
pluripotency regulation and restriction, stem cell 
biology and tissue repair process. 
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Introduction 
 
The temporal order of gene expression plays a 
fundamental rule to ensure lineage commitment and cell 
fate determination Brevini et al., 2007. In 1942, 
Waddington coined the term 'epigenetics', which was 
defined as “changes in phenotype without changes in 
genotype”. In recent years several studies have 
characterized the different mode of epigenetic 
regulation, such as DNA methylation, post-translational 
histone tail modifications, non-coding RNA control of 
chromatin structure, and nucleosome remodeling. All of 
them regulate the activation or repression of genes. 
Technological advances in epigenome analysis and 
pluripotent stem cell technologies have been driver for 
elucidating the epigenetic control of cellular identity 
during development and reprogramming.  
Here, we provide a brief overview of the main 
epigenetic mechanisms, such as DNA methylation and 
histone modifications. We then review the available 
knowledge on the possibility to erase the epigenetic 
memory through the use of cell reprogramming 
technologies. We also give prospective views of the 
epigenetic direct conversion of one cell type into 
another, in a safe  and robust way, for regenerative 
medicine. 
 
Cell commitment and Waddington model of 
epigenetic restriction 
 
Over 230 different cell types are present in an 
adult multicellular organism. Although they all derive 
from one single cell and are genetically identical 
(containing the same DNA sequence), they are able to 
differentiate in a tissue specific way and to respond to 
specific developmental cues. Indeed, at the end of the 
differentiation process, each cells is highly specialized 
and committed to a distinct determined fate. This is 
possible thanks to tissue-specific gene expression, 
timely regulated by epigenetic restrictions, that 
gradually limit cell potency (Hemberger et al., 2009) to 
a more limited phenotype-related expression pattern 
(Zhou and Melton, 2008). 
More than 60 years ago, these concepts have 
been nicely depicted by Conrad Waddington, who first 
used the term “epigenetics” in his very famous 
landscape to describe the idea that a phenotype arises by 
a program, defined by the genome, under the influence 
of the organism’s environment. In Waddington's 
metaphor, a ball represents the cell of an embryo, 
rolling from a non-committed, pluripotent condition 
down the hill, to a specific cell fate. The hill is marked 
by slopes and valleys representing the many different 
and complex process that characterize the events 
leading to cell differentiation. The ball is addressed 
along a progressively more restricted potency pathway, 
towards a favored position at the bottom of the hill, 
where the cell is unipotent and is characterized by a 
tissue specific differentiated state (Fig. 1). 
Currently, epigenetics is at the center of 
modern biology, since it is considered a fundamental 
tool to understand stem cell biology as well as cell 
differentiation and de-differentiation processes. 
 
 
 Brevini et al. Epigenetics, pluripotency and cell fate. 
 
62 Anim. Reprod., v.14, n.1, p.61-68, Jan./Mar. 2017 
 
Figure 1. Representation of Waddington model. A pluripotent cell rolls from a non-committed condition down to the 
bottom of the hill, where the cell is unipotent and is characterized by a tissue specific differentiated state. The hill is 
marked by slopes and valleys, representing the many different and complex process that characterize the events 
leading to cell differentiation. Recent studies have shown that differentiated cells of an adult organism can be forced 
in an upstream, counter-current direction up the differentiation hill, transiting along different states of increased 
potency. 
 
Epigenetic control mechanisms and “epigenetic 
memory” 
 
The term “epigenetics” refers to complex 
chemical modifications of DNA, RNA and associated 
proteins, that determine activation or silencing of 
certain genes, without any permanent loss or alteration 
of genetic material (Goldberg et al., 2007; Xie et al., 
2013). These mechanisms are responsible for the 
‘epigenetic memory’ that triggers the phenotypic 
stability of the differentiated cell during subsequent cell 
divisions (Zhu et al., 2013; Jost, 2014; Shipony et al., 
2014; Brevini et al., 2015). 
There are several types of epigenetic 
modifications (Table 1) that play a fundamental role in 
the regulation of chromatin structure and gene 
expression, namely histone post-translational 
modifications, covalent modifications of DNA, small 
(21- to 26-nt) non-coding RNAs, and recombinations of 
non-genic DNA (Goldberg et al., 2007). 
More in detail, histones can be subjected to 
acetylation, phosphorylation, methylation, 
SUMOylation, citrullination, ADP ribosylation, and 
ubiquitination (Spivakov and Fisher, 2007), that allow 
or prevent transcription factor and other protein access 
to DNA. 
In parallel, the DNA can be methylated 
trough a covalent addition of a methyl (CH3) group 
at the 5-carbon of the cytosine, that physically 
impedes the binding of transcription factor proteins 
to the gene (Choy et al., 2010) or recruits the methyl-
CpG-binding domain proteins (MBDs). This 
modification also induces histone remodeling and the 
formation of compact, inactive chromatin, known as 
heterochromatin. 
All these processes drive pluripotent cell 
differentiation and the acquisition of tissue specific 
epigenetic marks that are stable through the life span of 
a single individual and have been considered 
irreversible until not long ago. 
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Table 1. Mechanisms involved in epigenetic control and related epigenetic enzymes. 
Mechanism Epigenetic enzymes 
DNA  
Methylation 
DNA Methyltransferases 
DNA Demethylation Enzymes 
Methyl-CpG Binding Domains 
Histone  
Acetylation 
Histone Acetyltransferases 
Histone Deacetylases 
Bromodomains; Tandem PHD Fingers; Pleckstrin Homology Domains 
Histone Arginine Methylation 
Protein Arginine Methyltransferases 
Histone Demethylases 
Tudor Domains (recognize symmetrically dimethylated arginines); WD40 
Domains 
Histone Lysine Methylation 
Histone Lysine Methyltransferases 
Histone Lysine Demethylases 
Chromodomains; Tudor Domains; PHD Fingers; MBT Domains; ZF-CW 
Proteins; WD40 Domains; PWWP 
Histone Phosphorylation 
Kinases (JAK2, ATM/ATR, PKC, PKA, Haspin, Aurora B Kinase, RSK2, 
AMPK, MSK, MEK) 
Protein Serine/Threonine Phosphatases; Protein Tyrosine Phosphatases 
Chromoshadow Domains (phosphoTyrosine); 14.3.3 Proteins 
(phosphoSerine); BIR Domains; BRCT Proteins 
Histone Ubiquitination Ubiquitin E2 Conjugases; Ubiquitin E3 Ligases Deubiquitinating Enzymes 
 
 
Erasing of “epigenetic memory” 
 
During the last years, many studies 
demonstrated that, although generally stable in vivo, the 
differentiated state of an adult cell can be reversed and 
forced in an upstream, counter-current direction up the 
Waddington’s differentiation hill, along different states 
of increased potency (De Carvalho et al., 2010).  
In 2006, the generation of induced pluripotent 
cells (iPSCs; Takahashi and Yamanaka, 2006) paved the 
way for a search of the mechanisms involved in the 
erasure of “epigenetic memory” and the re-establishment 
of pluripotency. Takahashi et al. demonstrated that an 
adult somatic cell can be brought back to an increased 
potency state, through the ectopic expression of four 
transcription factors (TFs; Takahashi and Yamanaka, 
2006). Currently, various methodologies have been 
established for iPSC derivation, from virus-free (Okita 
et al., 2008, 2010; Kaji et al., 2009), to removable 
PiggyBac transposons (Woltjen et al., 2009), minicircle 
systems (Jia et al., 2010), episomal systems (Yu et al., 
2009), synthetic mRNAs (Kim et al., 2009; Zhou et al., 
2009; Warren et al., 2010), and microRNAs (Anokye-
Danso et al., 2011; Miyoshi et al., 2011). 
Nevertheless, cell reprogramming suffers from 
a number of severe limitations (Okita et al., 2007). In 
particular, its efficiency remains low (Mikkelsen et al., 
2008; Pasque et al., 2012; Gaspar-Maia et al., 2013; 
Sridharan et al., 2013; Nashun et al., 2015), the extreme 
stability of adult somatic cell epigenetic signature 
makes iPSCs prone to errors (Plath and Lowry, 2011), 
and the use of DNA constructs and the subsequent 
possibility of exogenous sequence integration preclude 
their clinical use for safety concerns (Stadtfeld et al., 
2008; Kim et al., 2009; Zhou and Freed, 2009; Seki et 
al., 2010). In order to circumvent these limits, small-
molecule compounds have been used to modulate the 
epigenetic state by inhibiting and/or activating, in a 
reversible way, specific signaling pathways (Huangfu et 
al., 2008; Ichida et al., 2009; Li et al., 2011; Hou et al., 
2013). A recent study revealed that the endogenous 
pluripotency program can be re-activated through the 
use of a combination of seven small-molecule 
compounds, namely valproic acid (VPA), CHIR99021, 
616452, TCP, Forskolin (FSK), 2-methyl-5-
hydroxytryptamine (2-Me- 5HT), and D4476 (Hou et 
al., 2013). Similarly, it was also demonstrated that the 
use of VPA, in combination with an embryonic stem 
cell (ESC) medium, is able to revert somatic cells into 
pluripotent ones, in the absence of any transgenes 
(Moschidou et al., 2012; Rim et al., 2012). 
These results represent a significant progress in 
cell reprogramming technology, demonstrating the 
possibility to use new approaches that avoid the 
presence of retroviral and/or lentiviral vectors, and the 
insertion of transgenes. However, the major concern 
related to the acquisition of a stable and persistent 
pluripotent state, remains unsolved. Indeed, the 
achievement of a stable pluripotency is an un-
physiological condition, since, physiologically is 
transient and limited to a short time window, during the 
first phases of embryonic development. Furthermore, 
iPSCs display cell instability (Wu and Zhang, 2010), are 
difficult to differentiate with an efficiency that rarely 
exceeds 30%, leaving mature cells mixed with 
undifferentiated and proliferating ones (Cohen and 
Melton, 2011). 
Currently, all these aspects, severely limit the 
use of these cells in regenerative medicine, although 
useful information may be draw when using iPSCs, as a 
model for a detailed understanding of cell plasticity and 
differentiation.
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Epigenetic conversion: an alternative erasing of 
“epigenetic memory” 
 
During the last years new approaches allowing 
the direct conversion of an adult mature cell into 
another differentiated cell type have been developed. 
These methods are based on the use of small molecules 
and epigenetic modifiers (Table 2), and avoid the use of 
transgenes, stably integrated into the genome. In 2004 
we can list the first paper reporting the ability of the 
small molecule reversine to increase cell plasticity, 
inducing lineage committed myoblasts to become 
multipotent mesenchymal progenitor cells (Chen et al., 
2004). The activity of this molecule was subsequently 
tested in several type of cells, including 3T3E1 
osteoblasts (Chen et al., 2007), human primary skeletal 
myoblasts (Chen et al., 2007), murine and human 
dermal fibroblasts (Anastasia et al., 2006), and 
confirming in all treated cells the induction of an 
increased plasticity. 
Since that time, several protocols that involve 
the use of epigenetic modifiers have been developed. 
They confirmed that specific chemical compounds can 
push cells to a transient less committed state, increasing 
cell plasticity for a relative short time-window, but 
sufficient to re-address an adult mature cell into another 
differentiated cell type (Harris et al., 2011; Pennarossa 
et al., 2013, 2014; Brevini et al., 2014; Mirakhori et al., 
2015; Chandrakanthan et al., 2016). 
A very general concept at the base of these 
experiments is that, among several mechanisms that 
drive cell differentiation, DNA methylation plays a 
fundamental role during both early embryonic 
development and cell lineage specification. To this 
purpose, de-methylating agents, which are well-
characterized DNA methyltransferase (DNMT) 
inhibitor, were selected and used to erase DNA 
epigenetic restrictions. An example comes from 5-
azacytidine (5-aza-CR), that, when used at low doses, 
substitutes for cytosine and incorporate into DNA and 
RNA during replication (Stresemann and Lyko, 2008; 
Aimiuwu et al., 2012), forming covalent adducts with 
DNMT1. Thanks to its powerful effects, 5-aza-CR is 
able to induce global DNA hypo-methylation 
(Christman, 2002; Stresemann and Lyko, 2008), gene 
reactivation (Jones, 1985), and can facilitate adult 
somatic cell switch from one phenotype to a different 
one (Taylor and Jones, 1979; Glover et al., 1986; Harris 
et al., 2011). 
In accordance with these findings, our 
laboratory demonstrated that an adult somatic cells can 
be converted into a new cell type after an 18 h exposure 
to 5-aza-CR (Pennarossa et al., 2013, 2014; Brevini et 
al., 2014, 2016). Cells acquired a ‘highly permissive 
state’ with significant changes in their phenotype and a 
specific gene regulatory response, that were paralleled 
by decrease in global DNA methylation. More in detail, 
following exposure to the demethylating agent, cells
exhibited reduced dimensions with large nuclei, 
displayed a global chromatin decondensation and 
expressed pluripotency-related genes such as OCT4, 
NANOG, REX1 and SOX2. These are common features 
of ESC, iPSC and, more in general, of pluripotent cells 
(Tamada et al., 2006). It is interesting to consider that 
this condition was transient and reversible, and, if 
returned to their standard culture medium, cells reverted 
to their original phenotype. Expression of pluripotency 
related genes decreased gradually within a few days 
(Pennarossa et al., 2013, 2014; Brevini et al., 2014).  
Once entered into the higher plasticity window, 
cells could easily be directed towards a different 
phenotype through the use of specific differentiation 
stimuli. In particular, adult skin fibroblasts, derived 
from different species namely human (Pennarossa et al., 
2013; Brevini et al., 2014), porcine (Pennarossa et al., 
2014), and dog (Brevini et al., 2016), were converted 
into pancreatic beta-cells through a three step pancreatic 
induction protocol. At the end of the epigenetic 
conversion, cells exhibited mature endocrine phenotype, 
expressing the main hormone and glucose sensor genes 
specific of the pancreatic tissue (Pennarossa et al., 2013, 
2014; Brevini et al., 2016). The converted cell ability to 
restore normo-glycaemia and stably maintain glucose 
levels was also confirmed in vivo using diabetic mice 
(Pennarossa et al., 2013, 2014). Notably, we also 
demonstrated that epigenetic conversion can be applied 
to different cell types, such as granulosa cells that were 
converted into muscle cells through the use of 5-aza-CR 
followed by a 15 day culture with human recombinant 
vascular endothelial growth factor (VEGF; Brevini et 
al., 2014). 
Furthermore, recent works carried out in other 
laboratories demonstrated the possibility to convert 
human skin fibroblasts into neural progenitor-like cells 
(Mirakhori et al., 2015) and mature bone and fat cells 
into tissue-regenerative multipotent stem (iMS) cells 
(Chandrakanthan et al., 2016) through the use of the de-
methylating agent 5-aza-CR, proving to be in agreement 
with our results. In addition, Cheng et al. reported that, 
using a cocktail containing inhibitors of histone 
deacetylation, glycogen synthase kinase and TGF-β 
pathway, it is possible to convert human and murine 
fibroblasts into proliferating chemical-induced neural 
progenitor cells (ciNPC), under physiological hypoxic 
conditions (5% O2; Cheng et al., 2015). 
Furthermore, recent experiments described the 
possibility to epigenetically convert human skin 
fibroblasts into mature Schwann cells through the use of 
the histone deacetylase (HDAC) inhibitor VPA (Thoma 
et al., 2014) . In that work, cells were stimulated with a 
two-step neural induction protocol, in order to obtain a 
transient population of proliferating neural precursors 
and, subsequently, terminally differentiated Schwann 
cells (iSCs), that showed neuro-supportive and 
myelination capacity, and expressed proteins specific of 
the peripheral nervous system. 
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Table 2. List of epigenetic modifiers, their targets and applications. 
Epigenetic Modifier (name and structure) Target Applications 
 
 
 
 
5-aza-cytidine 
 
 
 
 
 
DNA 
methyltransferase 
inhibitor 
Phenotype changes in eukaryotic 
cells; 
Transformation of  mesenchymal 
stromal cells and fibroblasts into 
hematopoietic cells; 
Epigenetic cell conversion 
 
 
 
 
5-aza-2′-deoxycytidine 
 
 
DNA 
methyltransferase 
inhibitor 
Alteration of primitive HSC/HPC 
fate; 
Increasing of cell plasticity for 
somatic cell nuclear transfer; 
Transcriptional reactivation of 
tumor suppressor genes 
 
 
Hydralazine 
 
 
 
DNA 
methyltransferase 
inhibitor 
Epigenetic modification to revert 
multidrug-resistant phenotype 
 
 
Zebularine 
 
 
 
 
DNA 
methyltransferase 
inhibitor 
Epigenetic reprogramming of yak 
fibroblasts for cloning; 
Epigenetic modification of bovine 
adipose stem cells 
 
 
Valproic acid 
 
 
 
 
HDAC inhibitor 
Dedifferentiation of amniotic fluid 
cells and of human dermal 
fibroblasts 
 
Vorinostat 
 
 
 
HDAC inhibitor Epigenetic reprogramming to restore chemosensitivity 
 
 
 
Trichostatin A 
 
 
HDAC inhibitor Dedifferentiation of EG; 
Increasing of cell plasticity for 
somatic cell nuclear transfer; 
Increase iPS formation efficiency; 
Alteration of primitive HSC/HPC 
fate 
 
 
Sodium butyrate 
 
 
HDAC inhibitor 
In combination with A-83-01, 
PD0325901, and PS48, enables 
reprogramming of human somatic 
cells transduced with Oct4 only 
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Conclusions 
 
The growing understanding of the epigenetic 
regulatory mechanisms controlling cell differentiation 
provides new perspective for both the embryology and 
the cell biology field. Accumulating evidence point to 
epigenetic modifications, such as histone modification 
and DNA methylation, as key cellular events that exert a 
precise control over gene expression and allow a 
dynamic crosstalk between genotype and phenotype, 
leading to cell fate commitment and tissue specification. 
This has, in turn, further widened our understanding of 
the regulatory pathways involved in cell 
reprogramming, transdifferentiation and conversion, and 
has boosted the use of epigenetic modifiers and small 
molecules to revert cells to high plasticity states and 
encourage the acquisition of terminal phenotype.  
Altogether the results accumulating have 
important implications for a better understanding of 
epigenetic cell fate control but is also advantageous for 
stem cell therapy and for regenerative medicine of 
human and animals. 
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